Streetbeat News

Regulatory

ELTX

Elicio Therapeutics announced interim data from the Phase 1 study of its investigational therapeutic cancer immunotherapy, ELI-002. The results were highlighted on Saturday.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:37 pm

ENVB

Enveric Biosciences (NASDAQ: ENVB) has received a notice of allowance from the USPTO for a patent application related to its EVM301 series of molecules, which are being developed as potential treatments for mental health disorders. The patent could significantly enhance the commercial potential for its EVM301 series drug candidates.

Portfolio Pulse from Vuk Zdinjak

June 05, 2023 | 1:14 pm

SPY

VGK

European Central Bank President Christine Lagarde stated that price pressures remain strong and underlying inflationary pressures are still high, with no clear evidence that they have peaked.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:06 pm

ATRA

Atara Biotherapeutics presented updated clinical effectiveness data for Tab-cel at the 2023 ASCO Meeting, showcasing promising results in treating patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:04 pm

TTOO

T2 Biosystems has submitted an application to the FDA for Breakthrough Device Designation for its Candida auris diagnostic test. The company plans to add C. auris detection to its FDA-cleared T2Candida Panel.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:01 pm

SPY

USO

VGK

Saudi Energy Minister expressed frustration with OPEC members not meeting oil output goals and seeks more transparency from Russia regarding oil output.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:52 pm

EVAX

FRZA

TMBR

Forza X1's tweet hints at something extraordinary, Timber Pharmaceuticals receives FDA CARC Waiver for TMB-001, and Evaxion's AI technology shows promising results in EVX-01 Phase 1 clinical trial.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:48 pm

TMBR

Timber Pharmaceuticals shares are trading higher after the FDA approved its TMB-001 treatment.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:36 pm

BKTI

BK Technologies has received FCC approval for its BKR 9000 multiband radio, which is expected to enhance the company's product offerings and potentially boost sales.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:32 pm

TMBR

The FDA has granted a dermal carcinogenicity waiver for Timber Pharmaceuticals' TMB-001, a topical isotretinoin formulated using the company's patented IPEG delivery system. This allows Timber to forgo a 2-year dermal rodent carcinogenicity study and accelerate the TMB-001 program. TMBR shares are up 87.90% at $2.80 during the premarket session.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 12:31 pm